CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

This study is a single-arm, open-label, prospective clinical trial, with patients suffering from refractory and relapsed acute myeloid leukemia as the subjects. It plans to enroll 10 cases to evaluate the safety and efficacy of sequential CD123+CLL-1 CAR-T cells followed by CD7 CAR-T cells treatment.

NCT Number	NCT07201727
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	AML - Acute Myeloid Leukemia
Enrollment	10 participants
Start Date	2025-09-30
Primary Completion	2028-05-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-01